Genmab Says Japan Approves Tivdak for Cervical Cancer

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

Genmab Says Japan Approves Tivdak for Cervical Cancer

, MT Newswires - 8:59 AM ET 3/27/2025 default

08:59 AM EDT, 03/27/2025 (MT Newswires) -- Genmab ( GMAB ) said Thursday that Japan's Ministry of Health, Labour and Welfare has approved Tivdak, or tisotumab vedotin, for advanced or recurrent cervical cancer that has progressed on or after chemotherapy.

The company said the approval was based on data from a late-stage trial involving 502 patients, which met its primary and secondary endpoints.

Genmab ( GMAB ) said the trial showed that Tivdak reduced the risk of death by 30% when compared to chemotherapy, with a median overall survival of 11.5 months for Tivdak and 9.5 for chemotherapy.

Shares of the company were up more than 1% in recent Thursday premarket activity.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.